Table 2.
Cytotoxicity of the Cys-linker-MMAE-based ADC in cancer cell lines in vitro.
| Cell Lines | HER2 Status | mil40-15 | mil40 | MMAE | Cys-15 | ||||
|---|---|---|---|---|---|---|---|---|---|
| IC50 (nM) | Max. Inhibition | IC50 (nM) | Max. Inhibition | IC50(nM) | Max. Inhibition | IC50 (nM) | Max. Inhibition | ||
| BT-474 | HER2+++ | 0.35 | 84.49% | 0.78 | 65.45% | 0.32 | 79.09% | 6.88 | 82.62% |
| HCC1954 | HER2+++ | 0.09 | 96.29% | 1753.53 | 70.36% | 0.07 | 97.54% | 2.31 | 98.86% |
| NCI-N87 | HER2+++ | 0.12 | 95.01% | 0.19 | 87.90% | 0.07 | 89.37% | 8.67 | 94.86% |
| MCF-7 | HER2− | 110.54 | 88.06% | >3438.25 | 49.43% | 0.29 | 93.14% | 51.23 | 91.13% |
| MDA-MB-468 | HER2− | 97.62 | 87.42% | 1388.43 | 59.13% | 0.17 | 87.37% | 11.11 | 85.75% |
Note: “+++” indicates the antigen HER2 is positive; “−” indicates the antigen HER2 is negative.